Handicapping the Avandia FDA panel

Journalists, bloggers and academics are weighing in on the FDA advisory panel that begins on Tuesday.

The single best thing I’ve read on the hearing is by Daniel Carpenter, a professor of government at Harvard who has a new book out about the FDA: Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Carpenter’s guest post on Pharmalot is a long, thoughtful analysis of the important issues that will be coming into play at this panel.

There’s no point in summarizing his ideas: Carpenter’s piece deserves to be read in its entirety. He eschews rhetoric and polemics in favor of a careful examination of the briefing documents in the light of a broader historical perspective on the FDA.

In the absence of technical problems CardioBrief is planning to live-blog and live-tweet the FDA hearing– or at least the more interesting parts. We’ll also keep you informed of other useful coverage of the hearing.

More reading:

CardioBrief invites readers to send links to other useful stories on the panel hearing, either via e-mail or the comments section.

Speak Your Mind